Ribociclib: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | ||
Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. | Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib inhibits the enzymes [[Cyclin Dependent Kinase-4|cyclin-dependent kinase 4]] (CDK4) and cyclin-dependent kinase 6 (CDK6). | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 11:40, 30 October 2023
| ||||||||||||
